Name | Number of supported studies | Average coverage | |
---|---|---|---|
endothelial cell | 16 studies | 39% ± 21% | |
ciliated cell | 15 studies | 38% ± 16% | |
fibroblast | 15 studies | 28% ± 11% | |
epithelial cell | 12 studies | 37% ± 19% | |
pericyte | 9 studies | 36% ± 16% | |
retinal rod cell | 8 studies | 40% ± 19% | |
progenitor cell | 7 studies | 27% ± 6% | |
mesothelial cell | 7 studies | 29% ± 10% | |
smooth muscle cell | 7 studies | 29% ± 9% | |
basal cell | 7 studies | 33% ± 15% | |
connective tissue cell | 6 studies | 35% ± 20% | |
astrocyte | 6 studies | 38% ± 12% | |
neuron | 6 studies | 48% ± 27% | |
adipocyte | 6 studies | 33% ± 22% | |
hematopoietic precursor cell | 5 studies | 30% ± 19% | |
myofibroblast cell | 5 studies | 31% ± 7% | |
vein endothelial cell | 5 studies | 32% ± 17% | |
oligodendrocyte precursor cell | 5 studies | 32% ± 10% | |
cardiac muscle cell | 5 studies | 21% ± 2% | |
Mueller cell | 5 studies | 39% ± 24% | |
GABAergic neuron | 4 studies | 28% ± 16% | |
interneuron | 4 studies | 30% ± 13% | |
capillary endothelial cell | 4 studies | 30% ± 10% | |
goblet cell | 4 studies | 36% ± 19% | |
glutamatergic neuron | 3 studies | 30% ± 14% | |
podocyte | 3 studies | 30% ± 10% | |
kidney distal convoluted tubule epithelial cell | 3 studies | 26% ± 2% | |
epithelial cell of proximal tubule | 3 studies | 22% ± 3% | |
abnormal cell | 3 studies | 51% ± 24% | |
neural crest cell | 3 studies | 32% ± 9% | |
granule cell | 3 studies | 31% ± 15% | |
club cell | 3 studies | 27% ± 7% | |
type I pneumocyte | 3 studies | 28% ± 10% | |
retinal ganglion cell | 3 studies | 50% ± 20% | |
cholangiocyte | 3 studies | 55% ± 18% | |
hematopoietic stem cell | 3 studies | 37% ± 17% | |
megakaryocyte-erythroid progenitor cell | 3 studies | 38% ± 18% | |
respiratory goblet cell | 3 studies | 44% ± 15% | |
brush cell | 3 studies | 28% ± 6% | |
erythrocyte | 3 studies | 38% ± 15% | |
mucus secreting cell | 3 studies | 38% ± 13% | |
enteroendocrine cell | 3 studies | 28% ± 10% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
intestine | 97% | 1349.95 | 933 / 966 | 96% | 37.99 | 507 / 527 |
stomach | 94% | 1000.67 | 337 / 359 | 93% | 38.13 | 265 / 286 |
thymus | 100% | 1513.26 | 651 / 653 | 85% | 35.49 | 513 / 605 |
skin | 98% | 4168.93 | 1777 / 1809 | 85% | 36.81 | 403 / 472 |
pancreas | 93% | 553.17 | 304 / 328 | 88% | 25.53 | 156 / 178 |
ovary | 86% | 1163.13 | 155 / 180 | 93% | 61.00 | 399 / 430 |
esophagus | 80% | 417.18 | 1157 / 1445 | 97% | 66.47 | 177 / 183 |
lung | 100% | 2195.10 | 578 / 578 | 76% | 42.66 | 882 / 1155 |
uterus | 99% | 1001.91 | 168 / 170 | 73% | 40.36 | 334 / 459 |
bladder | 100% | 734.62 | 21 / 21 | 61% | 23.38 | 309 / 504 |
kidney | 100% | 1366.26 | 89 / 89 | 36% | 8.81 | 320 / 901 |
adrenal gland | 100% | 1605.59 | 258 / 258 | 12% | 3.82 | 28 / 230 |
breast | 99% | 1034.21 | 455 / 459 | 12% | 3.55 | 135 / 1118 |
spleen | 100% | 843.20 | 241 / 241 | 0% | 0 | 0 / 0 |
adipose | 100% | 1427.23 | 1203 / 1204 | 0% | 0 | 0 / 0 |
heart | 94% | 908.13 | 812 / 861 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 89% | 18.43 | 71 / 80 |
peripheral blood | 75% | 695.87 | 701 / 929 | 0% | 0 | 0 / 0 |
liver | 20% | 72.23 | 45 / 226 | 41% | 9.68 | 166 / 406 |
prostate | 58% | 338.42 | 142 / 245 | 1% | 0.12 | 6 / 502 |
tonsil | 0% | 0 | 0 / 0 | 58% | 29.26 | 26 / 45 |
blood vessel | 47% | 231.27 | 631 / 1335 | 0% | 0 | 0 / 0 |
brain | 27% | 199.11 | 709 / 2642 | 19% | 5.24 | 136 / 705 |
muscle | 25% | 85.60 | 202 / 803 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 7% | 0.78 | 2 / 29 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0097009 | Biological process | energy homeostasis |
GO_0051028 | Biological process | mRNA transport |
GO_0106106 | Biological process | cold-induced thermogenesis |
GO_0070934 | Biological process | CRD-mediated mRNA stabilization |
GO_0001817 | Biological process | regulation of cytokine production |
GO_0009653 | Biological process | anatomical structure morphogenesis |
GO_0007399 | Biological process | nervous system development |
GO_0017148 | Biological process | negative regulation of translation |
GO_0005856 | Cellular component | cytoskeleton |
GO_0000932 | Cellular component | P-body |
GO_0005829 | Cellular component | cytosol |
GO_0005737 | Cellular component | cytoplasm |
GO_0010494 | Cellular component | cytoplasmic stress granule |
GO_0005634 | Cellular component | nucleus |
GO_0048027 | Molecular function | mRNA 5'-UTR binding |
GO_0045182 | Molecular function | translation regulator activity |
GO_1990247 | Molecular function | N6-methyladenosine-containing RNA reader activity |
GO_0003723 | Molecular function | RNA binding |
GO_0003730 | Molecular function | mRNA 3'-UTR binding |
GO_0090079 | Molecular function | translation regulator activity, nucleic acid binding |
GO_0005515 | Molecular function | protein binding |
Gene name | IGF2BP2 |
Protein name | Truncated insulin-like 2 growth factor 2-binding protein 2 Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2 mRNA-binding protein 2) (IMP-2) (Hepatocellular carcinoma autoantigen p62) (IGF-II mRNA-binding protein 2) (VICKZ family member 2) Insulin like growth factor 2 mRNA binding protein 2 |
Synonyms | VICKZ2 IMP2 |
Description | FUNCTION: RNA-binding factor that recruits target transcripts to cytoplasmic protein-RNA complexes (mRNPs). This transcript 'caging' into mRNPs allows mRNA transport and transient storage. It also modulates the rate and location at which target transcripts encounter the translational apparatus and shields them from endonuclease attacks or microRNA-mediated degradation (By similarity). Preferentially binds to N6-methyladenosine (m6A)-containing mRNAs and increases their stability . Binds to the 5'-UTR of the insulin-like growth factor 2 (IGF2) mRNAs . Binding is isoform-specific. Binds to beta-actin/ACTB and MYC transcripts. Increases MYC mRNA stability by binding to the coding region instability determinant (CRD) and binding is enhanced by m6A-modification of the CRD . . |
Accessions | Q9Y6M1 B3FTN5 ENST00000382199.7 [Q9Y6M1-2] ENST00000457616.6 ENST00000421047.3 [Q9Y6M1-3] ENST00000346192.7 [Q9Y6M1-1] F8W930 |